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The lipogenic transcription factor ChREBP dissociates hepatic
steatosis from insulin resistance in mice and humans. Benha-
med F, Denechaud PD, Lemoine M, Robichon C, Moldes M, Ber-
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J, Guillou H, Postic C. J Clin Invest 2012 Jun 1;122(6):2176–94.
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Abstract: Nonalcoholic fatty liver disease (NAFLD) is associated with
all features of the metabolic syndrome. Although deposition of excess
triglycerides within liver cells, a hallmark of NAFLD, is associated
with a loss of insulin sensitivity, it is not clear which cellular abnor-
mality arises ﬁrst. We have explored this in mice overexpressing
carbohydrate responsive element-binding protein (ChREBP). On a
standard diet, mice overexpressing ChREBP remained insulin sensi-
tive, despite increased expression of genes involved in lipogenesis/
fatty acid esteriﬁcation and resultant hepatic steatosis (simple fatty
liver). Lipidomic analysis revealed that the steatosis was associated
with increased accumulation of monounsaturated fatty acids
(MUFAs). In primary cultures of mouse hepatocytes, ChREBP overex-
pression induced expression of stearoyl-CoA desaturase 1 (Scd1), the
enzyme responsible for the conversion of saturated fatty acids (SFAs)
into MUFAs. SFA impairment of insulin-responsive Akt phosphoryla-
tion was therefore rescued by the elevation of Scd1 levels upon ChRE-
BP overexpression, whereas pharmacological or shRNA-mediated
reduction of Scd1 activity decreased the beneﬁcial effect of ChREBP
on Akt phosphorylation. Importantly, ChREBP-overexpressing mice
fed a high-fat diet showed normal insulin levels and improved insulin
signaling and glucose tolerance compared with controls, despite hav-
ing greater hepatic steatosis. Finally, ChREBP expression in liver biop-
sies from patients with nonalcoholic steatohepatitis was increased
when steatosis was greater than 50% and decreased in the presence
of severe insulin resistance. Together, these results demonstrate that
increased ChREBP can dissociate hepatic steatosis from insulin resis-
tance, with beneﬁcial effects on both glucose and lipid metabolism.
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E-mail address: charlton.michael@mayo.eduThe rise of non-alcoholic fatty liver disease (NAFLD) and non-
alcoholic steatohepatitis (NASH) as an important etiology of liver
disease has been remarkable. Querying PubMed in preparation
for writing this commentary revealed that a total of four articles
were published regarding NAFLD or NASH in 1992. In 2012 the
number was over 400. In the United States, which has been at
the crest of the global wave of obesity and metabolic syndrome,
NASH is already the third most common indication for liver
transplantation and is on a trajectory to become the most com-
mon [1]. The scale of the health burden of NAFLD is likely to
increase in parallel with continued increases in the prevalence
and severity of obesity. Despite the logarithmic increase in inter-
est and consequences, we understand surprisingly little about the
pathobiology of NAFLD and there are, as yet, no approved phar-
macotherapies for this condition.
A key facet of the epidemiology of NAFLD is that the majority
of patients with obesity do not have NASH and a majority of
patients with NASH do not have evidence of progressive ﬁbrosis
[8]. Although genetic factors, such as PNPLA3 genotype [6], and
intestinal ﬂora [7] may contribute to the histological severity of
NAFLD, the predictivity of PNPLA3 genotype and intestinal
microbiome composition for severity of liver disease is small.
Understanding the basis of the histological diversity of NAFLD
will be central to improving our ability to diagnose and treat
NAFLD. This will require a more granular understanding of the
interplay between nutrition and organ speciﬁc metabolism. The
article by Benhamed et al., in the Journal of Clinical Investigation
provides welcome new insight into some of the most basic
aspects of NAFLD and metabolic syndrome.
The net accumulation of triglycerides within the liver in the
context of chronic overnutrition is substantially mediated by
the glucose stimulated activation of the liver transcription factor
carbohydrate responsive element-binding protein (ChREBP) via
induction of L-pyruvate kinase (L-PK) [4]. Results of studies of
the role and impact of ChREBP in glucose and lipid metabolism
have been confusing, with global ChREBP deﬁciency resulting in
insulin resistance in one murine model [3] vs. improved hepatic
steatosis and insulin resistance in another [2]. Benhamed et al.,
hypothesized that these opposite phenotypes may be on the basis
of the fact that ChREBP controls both glycolysis and lipogenesis
and that the beneﬁcial effect of ChREBP deﬁciency may only be
apparent in the context of lipid overload. In order to test this
hypothesis, the authors conducted an elegant series of experi-
ments that should begin to fundamentally change the way we
think of hepatic lipid and carbohydrate metabolism.
The ﬁrst important observation is that, on a standard diet,
mice overexpressing ChREBP remain insulin sensitive despite13 vol. 59 j 178–179
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Fig. 1. Speciﬁc lipogenic effects of activation of ChREBP are shown. Glucose
transporter 2 (GLUT2) mediated glucose entry into hepatocytes results in
generation of xylulose-5-phosphate (X5P), which removes inhibitory phospho-
rylations on ChREBP-a, allowing binding of ChREBP-a to speciﬁc sequence
elements. ChREBP-a may also be activated by dietary induced increase in hepatic
ligands (oxysterols) for liver X receptors (LXRs). A stearoyl-CoA desaturase (SCD1)
and Elovl6 are expressed, with a net effect of proportionally greater synthesis of
mono-unsaturated fats (MUFA), oleic acid, and triglycerides (TGs), than palmitate
(PALM). The relative decrease in PALM concentration decreases CAAT/enhancer
binding homologous protein (CHOP) activation. Decreased PALM concentration
also leads to increased Akt phosphorylation with subsequently enhanced energy
production and insulin sensitivity.
JOURNAL OF HEPATOLOGYincreased lipogenesis/fatty acid esteriﬁcation and resultant hepa-
tic steatosis. Triglyceride accumulation and steatosis thus do not
inevitably cause insulin resistance. The second important obser-
vation is that ChREBP-overexpressing mice fed a high-fat diet
showed normal insulin levels and improved insulin signaling
and glucose tolerance compared with controls despite having
greater hepatic steatosis. This effect seems to be mediated by
ChREBP modifying the MUFA/SFA balance in favor of MUFA.
Together these ﬁndings provide new evidence that increased
ChREBP can dissociate hepatic steatosis from insulin resistance,
with beneﬁcial effects on both glucose and lipid metabolism.
The authors’ observations that ChREBP expression in liver biop-
sies from patients with NASH was relatively more abundant
when steatosis was greater than 50%, and relatively less abun-
dant in the presence of severe insulin resistance, supports this
conclusion. The authors also provide novel mechanistic insight
into ChREBP action through the identiﬁcation of the lipogenic ste-
aroyl-CoA desaturase (SCD1), which introduces a cis double bond
in the D9 position of saturated 16- and 18-carbon fatty acids
acyl-CoA substrates, as a key ChREBP target gene and likely effec-
tor of the beneﬁcial effects of ChREBP expression.
There are several important implications to this work. The
most obvious is that the concept that ChREBP expression pro-
motes insulin resistance and deleterious hepatic fat accumulationJournal of Hepatology 201should be reconsidered. Indeed, the results reported by Benha-
med et al. suggest that ChREBP activation might be explored as
a potential therapeutic target in NAFLD and metabolic syndrome
(Fig. 1 summarizes likely effects of ChREBP activation). The recent
report that ChREBP greatly ampliﬁes the glucose effect on beta
cell proliferation [5], increases the theoretical potential of ChRE-
BP as a novel drug target. The results of Benhamed et al. also con-
tribute to the rationale for changing how we think of ‘‘insulin
sensitivity’’. Insulin has complex and diverse effects on protein
metabolism (primarily inhibits protein degradation but also has
differential effects on protein synthesis), carbohydrate metabo-
lism, and lipid metabolism. Clearly, the effects of insulin on car-
bohydrate and lipid metabolism can be dissociated and should
be considered as distinct facets of insulin biology. Finally, we
are overdue to reduce the use of the term high fat diet (HFD), par-
ticularly when referring to studies of NAFLD and NASH. When it
comes to dietary fat, Benhamed et al. have highlighted the fact
that composition is critical. Based on these results a HFD rich in
oleic acid, for example, might be expected to enhance ChREBP
expression, with subsequently favorable changes in hepatic lipid
abundance and composition, and enhance carbohydrate insulin
sensitivity. A diet relatively rich in saturated fats or cholesterol
might be predicted to have the opposite effects.
The article by Benhamed et al. has limitations, e.g., the appli-
cability of adenoviral and in vitro studies to the complex human
condition. Taken as a whole, however, this work is likely to be a
landmark.Conﬂict of interest
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